While certain elements of clinical trial decentralisation existed before the COVID-19 pandemic, they were not commonly used across trials. The pandemic forced the research industry to adopt and deliver decentralised clinical trials, with 80% of CROs predicting that they will conduct decentralised trials by 2021-2022 (EndpointsNews Survey, May 2021). This transition was driven by the need for urgent public health trials to quickly find treatments and vaccines for COVID-19, where delivering trial procedures remotely to participants became a necessity.